Global partnerships Evive Biotech operates across the US, Singapore, and China, signaling international collaboration potential. Sales opportunities exist through strategic co-development, licensing, and distribution partnerships to scale their novel biological therapies in diverse markets.

Biologics focus Specialization in oncology, inflammatory, and metabolic diseases with proprietary technology platforms suggests opportunities for CRO services, assay development, contract research, and early-phase clinical support targeting biotech firms seeking specialized biologics capabilities.

Regulatory edge In-house regulatory expertise and global management experience indicate potential to offer regulatory consulting, dossier preparation, and expedited pathway support for partners aiming to navigate international approvals efficiently.

Mid-market target With a revenue range of 25-50 million and funding of 70 million, Evive sits between small and mid-cap Biotech, presenting opportunities for strategic investment, equity partnerships, or collaboration on late-stage development and commercialization deals.

Recent collaborations Recent partnerships and collaborations with Nona Biosciences and Nonabio highlight a proven interest in accelerating discovery and development, suggesting sales opportunities in platform licensing, antibody discovery services, and joint research ventures.